Hittu Matta, PhD

Associate Professor Of Research Medicine

Image of Hittu Matta, PhD
Is this your profile? Click to edit

Overview

Dr. Matta earned her Master’s and PhD in Microbiology followed by a fellowship at The Hamon Center for Therapeutic and Oncology Research, University of Texas Southwestern Medical Center.

Dr. Matta’s research interests include KSHV-associated malignancies and drug development.

Publications

  • A novel thermostable beetle luciferase based cytotoxicity assay Sci Rep. 2021 05 11; 11(1):10002. . View in PubMed
  • Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma Sci Rep. 2020 03 31; 10(1):5712. . View in PubMed
  • A Fast and Sensitive Luciferase-based Assay for Antibody Engineering and Design of Chimeric Antigen Receptors Sci Rep. 2020 02 11; 10(1):2318. . View in PubMed
  • A novel luciferase-based assay for the detection of Chimeric Antigen Receptors Sci Rep. 2019 02 13; 9(1):1957. . View in PubMed
  • Development and characterization of a novel luciferase based cytotoxicity assay Sci Rep. 2018 01 09; 8(1):199. . View in PubMed
  • Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors Oncogene. 2016 Apr 07; 35(14):1797-810. . View in PubMed
  • NEMO is essential for Kaposi’s sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death, and its N-terminal 251 residues are sufficient for this process J Virol. 2014 Jun; 88(11):6345-54. . View in PubMed
  • Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors Oncogene. 2014 May 29; 33(22):2928-37. . View in PubMed
  • A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-? B. Clin Cancer Res. 2013 Sep 15; 19(18):5016-26.. View in PubMed
  • Kaposi’s sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-? B activation. J Virol. 2013 Feb; 87(4):2242-52.. View in PubMed
  • A computational profiling of changes in gene expression and transcription factors induced by vFLIP K13 in primary effusion lymphoma PLoS One. 2012; 7(5):e37498. . View in PubMed
  • PLoS One. 2012; 7(5):e36601. . View in PubMed
  • Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells J Biol Chem. 2011 Aug 12; 286(32):27988-97. . View in PubMed
  • A20 is induced by Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 and blocks K13-induced nuclear factor-kappaB in a negative feedback manner J Biol Chem. 2011 Jun 17; 286(24):21555-64. . View in PubMed
  • Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice Cancer Biol Ther. 2010 Nov 15; 10(10):1033-40. . View in PubMed
  • X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation Clin Cancer Res. 2010 Feb 15; 16(4):1140-8. . View in PubMed
  • Integrated microarray and multiplex cytokine analyses of Kaposi’s Sarcoma Associated Herpesvirus viral FLICE Inhibitory Protein K13 affected genes and cytokines in human blood vascular endothelial cells BMC Med Genomics. 2009 Aug 06; 2:50. . View in PubMed
  • Induction of CCL20 production by Kaposi sarcoma-associated herpesvirus: role of viral FLICE inhibitory protein K13-induced NF-kappaB activation Blood. 2009 May 28; 113(22):5660-8. . View in PubMed
  • K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis PLoS One. 2007 Oct 24; 2(10):e1067. . View in PubMed
  • Kaposi’s sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB kinase complex to selectively activate NF-kappaB without JNK activation J Biol Chem. 2007 Aug 24; 282(34):24858-65. . View in PubMed
  • In primary effusion lymphoma cells, MYB transcriptional repression is associated with v-FLIP expression during latent KSHV infection while both v-FLIP and v-GPCR become involved during the lytic cycle Br J Haematol. 2007 Aug; 138(4):487-501. . View in PubMed
  • Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice Proc Natl Acad Sci U S A. 2005 Sep 06; 102(36):12885-90. . View in PubMed
  • Kaposi’s sarcoma associated herpes virus-encoded viral FLICE inhibitory protein activates transcription from HIV-1 Long Terminal Repeat via the classical NF-kappaB pathway and functionally cooperates with Tat Retrovirology. 2005 Feb 15; 2:9. . View in PubMed
  • The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells Cancer Biol Ther. 2005 Jan; 4(1):77-82. . View in PubMed
  • An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha J Biol Chem. 2004 Sep 17; 279(38):39358-65. . View in PubMed
  • Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP) Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9399-404. . View in PubMed
  • Molecular genetic analysis of human herpes virus 8-encoded viral FLICE inhibitory protein-induced NF-kappaB activation J Biol Chem. 2003 Dec 26; 278(52):52406-11. . View in PubMed
  • Use of adeno-associated viral vector for delivery of small interfering RNA Oncogene. 2003 Aug 28; 22(36):5712-5. . View in PubMed
  • Use of lentiviral vectors for delivery of small interfering RNA Cancer Biol Ther. 2003 Mar-Apr; 2(2):206-10. . View in PubMed
  • The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation Blood. 2003 Mar 01; 101(5):1956-61. . View in PubMed
  • Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification Oncogene. 2002 Dec 05; 21(55):8510-4. . View in PubMed
  • Role of MRIT/cFLIP in protection against chemotherapy-induced apoptosis Cancer Biol Ther. 2002 Nov-Dec; 1(6):652-60. . View in PubMed
  • Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines Cancer Res. 2002 Oct 15; 62(20):5897-901. . View in PubMed